Seres Therapeutics, Inc. (NASDAQ: MCRB) today announced that new
preclinical data supporting the development of microbiome therapeutics for
immuno - oncology (leveraging gut microbiota to impact tumor immunotherapy) 1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago.